#USA #biotechnology #HIV Prevention #Bradenton #Continuity Biosciences

Continuity Biosciences Secures $9.6 Million Grant for Revolutionary HIV Prevention Implant

Continuity Biosciences, a clinical-stage biotechnology company, has announced the receipt of a substantial grant amounting to $9.6 million from the Gates Foundation. The funding is aimed at the development of a breakthrough subcutaneous implant that promises ultra-long-acting delivery of antiretroviral (ARV) medication for pre-exposure prophylaxis (PrEP) against HIV, particularly targeting low- to middle-income countries where the epidemic is most pronounced.

Background and Context

In recent years, despite significant advancements in medicine, the fight against HIV has faced numerous hurdles. The emergence of about 1.2 million new HIV infections globally in 2025, as reported by UNAIDS, underscores the urgent need for innovative preventive measures. Traditional methods such as daily oral PrEP and injectable solutions, while effective, often struggle with adherence issues, especially in resource-limited settings. This is where the new implant from Continuity Biosciences comes into play.

What is the New Implant?

The implant is designed to release a preventive ARV medication steadily over several years following a single subcutaneous insertion. This creates a robust alternative to daily pills and regular injections, significantly reducing the need for ongoing healthcare interactions and improving accessibility for those at high risk of contracting HIV. Ramakrishna “Krishna” Venugopalan, co-founder and CEO of Continuity Biosciences, explained that the challenge wasn't just about accessing effective medications but also about the ongoing burden of maintaining consistent protection. The implant aims to shift the paradigm by providing long-lasting protection.

How Does It Work?

Utilizing advanced nanofluidic drug delivery technology, the implant is engineered to allow for precise control over the release of medication. This technology involves the use of meticulously designed channels that enable a constant drug release rate over an extended period. With the potential to provide years of drug exposure, this approach alleviates the need for repeated medical intervention and follow-ups, addressing one of the most substantial barriers to consistent medication adherence.

Next Steps in the Development Process

The generous grant will facilitate critical studies necessary for the submission of an Investigational New Drug (IND) application, marking the beginning of Phase 1 clinical trials in humans. As the world shifts towards better healthcare solutions, the development of this implant signifies a vital step toward understanding and combating the spread of HIV in high-risk demographics.

Continuity is committed to ensuring that the technological advancements resulting from this grant will be accessible globally, particularly in low-income regions. The response from the Gates Foundation acknowledges not only the scientific merits of the project but also the importance of equitable access in healthcare solutions.

Broadening Horizons

Beyond HIV prevention, Continuity Biosciences is also exploring the potential applications of its drug delivery platforms in other therapeutic areas, including Type 1 diabetes, oncology, and endocrinology. The company is running ongoing studies, including a first-in-human trial for its iontophoretic platform aimed at pancreatic cancer treatment.

Conclusion

In summary, Continuity Biosciences' initiative stands to revolutionize the way HIV prevention is approached, moving towards a model that could significantly enhance the convenience, effectiveness, and accessibility of preventive care. With a focus on precision medicine and long-lasting solutions, this groundbreaking implant represents hope for many vulnerable populations worldwide. As the clinical trials progress, the medical community will be watching closely for the promising disruptions this innovation could herald in the quest to curb the HIV epidemic.